VYNE Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
VYNE Therapeutics has a total shareholder equity of $88.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $97.7M and $9.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$93.25m |
| Equity | US$88.74m |
| Total liabilities | US$8.95m |
| Total assets | US$97.69m |
Recent financial health updates
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Recent updates
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10VYNE Therapeutics closes capital raise of $50M
Jan 29What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?
Jan 06VYNE Therapeutics reports successful FDA meeting for FCD105 in acne
Dec 17Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?
Dec 08Financial Position Analysis
Short Term Liabilities: VYNE's short term assets ($96.0M) exceed its short term liabilities ($7.5M).
Long Term Liabilities: VYNE's short term assets ($96.0M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: VYNE is debt free.
Reducing Debt: VYNE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VYNE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VYNE has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 12.1% each year